NodThera
- Company typePrivate
- Founded2016
- HeadquartersLittle Chesterford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
NodThera firmographics
Firmographics- Name
- NodThera
- Legal name
- NodThera
- Website
- https://nodthera.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
NodThera industry classification
Industry- Product category
- Inflammatory Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where NodThera is headquartered
LocationHeadquarters
- HQ city
- Little Chesterford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
NodThera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Marketing channels5 records
NodThera product offering
Product offeringCore offering
NodThera is a clinical-stage biotechnology company developing a portfolio of brain-penetrant, oral small-molecule NLRP3 inflammasome inhibitors designed to treat chronic cardiometabolic and neuroinflammatory diseases. The company's pipeline includes three clinical-stage drug candidates: Ruvonoflast (NT-0796) as the lead molecule for cardiometabolic diseases currently in Phase 2 trials, NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1, and NT-0249 as a CSF-penetrant Phase 2-ready candidate.
Product overview
NodThera is a clinical-stage biotech company developing a portfolio of brain-penetrant oral small-molecule NLRP3 inhibitors to treat cardiometabolic and neuroinflammatory diseases. The company's pipeline consists of three clinical-stage programs: Ruvonoflast (NT-0796) as the lead candidate for cardiometabolic diseases currently in Phase 2; NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1; and NT-0249 as a CSF-penetrant inhibitor for chronic inflammatory diseases that is Phase 2-ready. All candidates target the NLRP3 inflammasome to address upstream inflammation drivers while preserving immune defense capability.
Differentiator
Problem solved
Functional benefit
Products and services
- Ruvonoflast (NT-0796) Lead molecule and brain-penetrant oral NLRP3 inhibitor designed to reduce persistent inflammation driving cardiometabolic diseases. Currently in two Phase 2 clinical trials (RESOLVE-1 and RESOLVE-2) for cardiometabolic diseases. Targets patients with atherosclerotic cardiovascular disease (ASCVD) with residual inflammatory risk. Demonstrated 82% reduction in hsCRP in clinical studies.
- NT-0150 Next-generation brain-penetrant NLRP3 inhibitor being developed for neuroinflammatory diseases. Phase 1 clinical studies are underway. Demonstrated excellent preclinical efficacy reducing central and peripheral inflammatory markers across multiple animal models.
- NT-0249 Potent NLRP3 inhibitor with excellent cerebrospinal fluid (CSF) penetration optimized for chronic inflammatory diseases of the body. Currently Phase 2-ready.
Quantifiable outcome
- Ruvonoflast lowered hsCRP by 82% in patients at high risk of ASCVD
- +5 more outcomes
Companies that use NodThera
Customer profileSegments3 records
Ideal customer profiles1 record
NodThera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NodThera partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
NodThera competitors and assessment
Company assessmentDirect peers
- Olatec Therapeutics: Direct NLRP3 inflammasome inhibitor peer developing dapansutrile in cardiometabolic and inflammatory indications. Closely comparable mechanism, target indications, and clinical-stage positioning to NodThera.
- Inflazome (Roche): NLRP3 inhibitor developer acquired by Roche in 2020; one of NodThera's most direct competitors and a comparable oral small-molecule NLRP3 play, now with Roche's resources.
- IFM Tre (Novartis): NLRP3 antagonist program originally developed by IFM Tre and acquired by Novartis. Directly comparable mechanism and inflammatory-disease focus, now backed by large-pharma resources.
Emerging players
- Zydus Cadila (NLRP3 programs): India-based pharma with internal NLRP3 inflammasome inhibitor programs in cardiometabolic indications; comparable mechanism, partial geographic overlap.
- Kymera Therapeutics: Clinical-stage biotech developing novel small-molecule immunology/inflammation therapies (including IRAK4 degrader); Don Nicholson (NodThera's chairman) is also on Kymera's board. Comparable clinical-stage inflammation focus.
- Bicycle Therapeutics: Clinical-stage biotech founded by NodThera's CSO Alan Watt (as acting CSO). Comparable clinical-stage size and inflammation/oncology therapeutic area positioning.
Broad incumbents
- Bristol Myers Squibb (NLRP3 via IFM): Big pharma that had NLRP3 programs via the IFM Due (originally with BMS) and broader inflammation pipeline; comparable therapeutic area with vastly greater scale.
- Novo Nordisk: Investor in NodThera and developer of semaglutide; overlapping cardiometabolic/obesity franchise where NodThera's anti-inflammatory approach could be complementary or competitive.
- AstraZeneca: Major player in cardiometabolic disease with the Farxiga (dapagliflozin) franchise and an obesity franchise led by ex-NodThera board member Elisabeth Björk; overlapping therapeutic area and large commercial scale.
- Amgen: Major inflammation and cardiometabolic player (Repatha, Otezla); comparable therapeutic area where NodThera's CMO Jyothis George previously led obesity medical affairs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
NodThera social profiles
Digital presenceNodThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
NodThera leadership team
Management profileNumber of profiles
Profiles12 records
NodThera funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NodThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NodThera
What does NodThera do?
NodThera is a clinical-stage biotechnology company developing a portfolio of brain-penetrant, oral small-molecule NLRP3 inflammasome inhibitors designed to treat chronic cardiometabolic and neuroinflammatory diseases. The company's pipeline includes three clinical-stage drug candidates: Ruvonoflast (NT-0796) as the lead molecule for cardiometabolic diseases currently in Phase 2 trials, NT-0150 as a next-generation brain-penetrant inhibitor for neuroinflammatory diseases in Phase 1, and NT-0249 as a CSF-penetrant Phase 2-ready candidate.
Is NodThera a public or private company?
NodThera is a private company. It is classified as venture growth investor backed and is currently operating.
When was NodThera founded?
NodThera was founded in 2016. It employs 11 to 50 people.
Where is NodThera based?
NodThera is headquartered in Little Chesterford, United Kingdom, in the Europe region.
Who are NodThera's main competitors?
Direct peers on record are Olatec Therapeutics, Inflazome (Roche) and IFM Tre (Novartis). Emerging players are Zydus Cadila (NLRP3 programs), Kymera Therapeutics and Bicycle Therapeutics. Broad incumbents are Bristol Myers Squibb (NLRP3 via IFM), Novo Nordisk, AstraZeneca and Amgen.
Does NodThera have an API?
No public API is recorded for NodThera.
What industry is NodThera in?
NodThera's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.